PLIANT THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
PLIANT THERAPEUTICS, INC. (PLRX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 12.09 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 11.93M shares, a 4.83% increase year-over-year.
- PLIANT THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 11.38M shares, a 28.37% increase year-over-year.
- PLIANT THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 8.86M shares, a 17.39% increase year-over-year.
- PLIANT THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 7.55M shares, a 45.09% increase year-over-year.
- PLIANT THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 8.31M shares, a 9.95% decline from fiscal 2024.
- PLIANT THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 9.23M shares, a 13.20% increase from fiscal 2023.
- PLIANT THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 8.16M shares, a 26.82% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 6.43M shares, a 76.61% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 12.09M shares 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 11.93M shares 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 8.31M shares 10-K · filed 2026-03-11 | |||
| 2025-09-30 | 9.10M shares 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 10.10M shares 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 11.38M shares 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | 9.23M shares 10-K · filed 2026-03-11 | |||
| 2024-09-30 | 9.21M shares 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | 9.57M shares 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 8.86M shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 8.16M shares 10-K · filed 2025-03-03 | |||
| 2023-09-30 | 7.77M shares 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 7.79M shares 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 7.55M shares 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | 6.43M shares 10-K · filed 2025-03-03 | |||
| 2022-09-30 | 6.00M shares 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 5.42M shares 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 5.20M shares 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 3.64M shares 10-K · filed 2024-02-27 | |||
| 2021-09-30 | 3.73M shares 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | 3.91M shares 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | 4.03M shares 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | 3.12M shares 10-K · filed 2022-03-01 | |||
| 2020-09-30 | 2.97M shares 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | 2.73M shares 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | 25.28M shares 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | 20.09M shares 10-K · filed 2022-03-01 | |||
| 2019-09-30 | 16.42M shares 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | 16.50M shares 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |